Work

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)

Year: 2011

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v118.21.768.768

Authors: Joseph G. Jurcic, Todd L. Rosenblat, Michael R. McDevitt, Neeta Pandit-Taskar, Jorge A. Carrasquillo, Suzanne M. Chanel, Kevin Zikaras, Mark G. Frattini, Peter G. Maslak, Dragan Cicic, Steven M. Larson, David A. Scheinberg

Institutions: Memorial Sloan Kettering Cancer Center, Actinium Pharmaceuticals (United States)

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2580248382

FWCI: 2.445

Cites:

Cited by: 45

Related to: 10